The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Hannah M. Dahn, Dalhousie University
  • ,
  • Liesbeth J. Boersma, Maastricht University
  • ,
  • Dirk de Ruysscher, Maastricht University
  • ,
  • Icro Meattini, Azienda Ospedaliera Careggi
  • ,
  • Birgitte V. Offersen
  • Jean Philippe Pignol, Dalhousie University
  • ,
  • Cynthia Aristei, University of Perugia
  • ,
  • Yazid Belkacemi, Hopital Henri Mondor, Universite Paris XII
  • ,
  • Dori Benjamin, Sheba Medical Center at Tel Hashomer
  • ,
  • Nuran Bese, Research Institute of Senology Acibadem
  • ,
  • Charlotte E. Coles, Department of Oncology
  • ,
  • Pierfrancesco Franco, University of Eastern Piedmont, University Hospital "Maggiore della Carità
  • ,
  • Alice Ho, Harvard University
  • ,
  • Sandra Hol, Instituut Verbeeten
  • ,
  • Reshma Jagsi, University of Michigan, Ann Arbor
  • ,
  • Anna M. Kirby, Royal Marsden NHS Foundation Trust
  • ,
  • Livia Marrazzo, Azienda Ospedaliera Careggi
  • ,
  • Gustavo N. Marta, Hospital Sirio-Libanes
  • ,
  • Meena S. Moran, Yale University
  • ,
  • Alan M. Nichol, University of British Columbia
  • ,
  • Henrik D. Nissen, Syddansk Universitet
  • ,
  • Vratislav Strnad, Friedrich-Alexander University Erlangen-Nürnberg
  • ,
  • Yvonne E. Zissiadis, Hollywood Radiation Oncology
  • ,
  • Philip Poortmans, University of Antwerp
  • ,
  • Orit Kaidar-Person, Sheba Medical Center at Tel Hashomer, Tel Aviv University

Purpose: Post mastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality for selected patients. Bolus overcomes the skin-sparing effect of external-beam radiotherapy, ensuring adequate dose to superficial regions at risk of local recurrence (LR). This systematic review summarizes the current evidence regarding the impact of bolus on LR and acute toxicity in the setting of PMRT. Results: 27 studies were included. The use of bolus led to higher rates of acute grade 3 radiation dermatitis (pooled rates of 9.6% with bolus vs. 1.2% without). Pooled crude LR rates from thirteen studies (n = 3756) were similar with (3.5%) and without (3.6%) bolus. Conclusions: Bolus may be indicated in cases with a high risk of LR in the skin, but seems not to be necessary for all patients. Further work is needed to define the role of bolus in PMRT.

OriginalsprogEngelsk
Artikelnummer103391
TidsskriftCritical Reviews in Oncology/Hematology
Vol/bind163
ISSN1040-8428
DOI
StatusUdgivet - jul. 2021

Bibliografisk note

Publisher Copyright:
© 2021 Elsevier B.V.

Se relationer på Aarhus Universitet Citationsformater

ID: 220294439